Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GEN 001 - Genome and Company

Next Previous
X
Search
Drug Profile

GEN 001 - Genome and Company

Alternative Names: GEN-001 - Genome & Company; LR-20011

Latest Information Update: 17 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genome & Company
  • Developer Genome & Company; Jeonbuk National University; Merck KGaA; Merck Sharp & Dohme; Pfizer; Seoul National University
  • Class Antineoplastics; Bacteria; Immunotherapies
  • Mechanism of Action Bacteria replacements; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Biliary cancer; Gastric cancer; Solid tumours

Most Recent Events

  • 17 Apr 2024 GEN 001 is still in phase I development in Solid-tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO, Capsule) (NCT04601402)
  • 24 Jan 2024 Efficacy data from a phase II trial in Gastric cancer released by Genome & Company
  • 24 Jan 2024 Genome & Company plans clinical trials for Gastric cancer (Second-line therapy or greater) (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top